Compare CCS & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCS | HROW |
|---|---|---|
| Founded | 2000 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2014 | 2008 |
| Metric | CCS | HROW |
|---|---|---|
| Price | $61.39 | $33.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $64.80 | ★ $69.86 |
| AVG Volume (30 Days) | 227.5K | ★ 453.1K |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | ★ 71.43 |
| EPS | ★ 2.09 | N/A |
| Revenue | ★ $4,117,816,000.00 | N/A |
| Revenue This Year | N/A | $31.62 |
| Revenue Next Year | $10.84 | $50.77 |
| P/E Ratio | $28.97 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $47.28 | $28.54 |
| 52 Week High | $76.00 | $54.98 |
| Indicator | CCS | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 34.67 | 31.95 |
| Support Level | $60.46 | $32.74 |
| Resistance Level | $61.13 | $36.37 |
| Average True Range (ATR) | 1.89 | 1.58 |
| MACD | -0.85 | -0.43 |
| Stochastic Oscillator | 14.61 | 2.21 |
Century Communities Inc is engaged in the development, design, construction, marketing and sale of single-family attached and detached homes. The company builds and sells homes under its Century Communities and Century Complete brands. Its reportable segments for homebuilding operations are: i) West (California and Washington) ii) Mountain (Arizona, Colorado, Nevada and Utah), iii) Texas, iv) Southeast (Florida, Georgia, North Carolina, South Carolina and Tennessee), v) Century Complete (Alabama, Arizona, Florida, Georgia, Indiana, Kentucky, Michigan, North Carolina, and South Carolina). The company's other reportable segments include: Financial Services and Century Living. The company derives the majority of its revenue from the sale of new homes in the Mountain segment.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.